Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport

Bioconjugate Chemistry

Volumn 17, Issue 6, 2006, Pages 1568-1581

  Roche, Dominique ^a   Greiner, Jacques ^a   Aubertin, Anne Marie ^b   Vierling, Pierre ^a  

^a CNRS   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; CELLS; CYTOLOGY; MONOLAYERS;

ANTI-HIV ACTIVITY; BIOLOGICAL EVALUATION; CACO-2 CELLS; HIV-PROTEASE INHIBITORS; IN-VITRO; PRODRUGS; SAQUINAVIR; THERAPEUTIC POTENTIALS; TRANSEPITHELIAL TRANSPORT;

HYDROLYSIS;

GLUCOSE; INDINAVIR; MANNOSE; MANNOSE INDINAVIR DERIVATIVE; MANNOSE NELFINAVIR DERIVATIVE; MANNOSE SAQUINAVIR DERIVATIVE; NELFINAVIR; PRODRUG; PROTEINASE INHIBITOR; SAQUINAVIR; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL SPECIFICITY; CELL TRANSPORT; CONTROLLED STUDY; DEPROTECTION REACTION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; GLUCOSE METABOLISM; HALF LIFE TIME; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROLYSIS; IN VITRO STUDY; INTESTINE EPITHELIUM; PROTEINASE INHIBITION; TISSUE SPECIFICITY;

EID: 33845218464     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060210m     Document Type: Article

References (76)

1. Gulick, R. M. (2002) Protease inhibitors: clinical efficacy. Infect. Dis. Ther. 25, 179-236.
2. Blankson, J. N., Persaud, D., and Siliciano, R. F. (2002) The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557-593.
3. Chun, T.-W., and Fauci, A. S. (1999) Latent reservoirs of HIV: obstacles to the eradication of virus. Proc. Natl. Acad. Sci. U.S.A. 96, 10958-10961.
4. Chun, T.-W., Stuyver, L., Mizell, S. B., Ehler, L. A., Mican, J. A. M., Baseler, M., Lloyd, A. L., Nowak, M. A., and Fauci, A. S. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 13193-13197.
5. Li, X., and Chan, W. K. (1999) Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv. Drug Deliv. Rev. 39, 81-103.
6. Taylor, S., and Pereira, A. (2000) Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med. 1, 18-22.
7. Bickel, U., Yoshikawa, T., and Pardridge, W. M. (2001) Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev. 46, 247-279.
8. Calogeropoulou, T., Detsi, A., Lekkas, E., and Koufaki, M. (2003) Strategies in the design of prodrugs of anti-HIV agents. Curr. Top. Med. Chem. 3, 1467-1495.
9. Vierling, P., and Greiner, J. (2003) Prodrugs of HIV protease inhibitors. Curr. Pharm. Des. 9, 1755-1770.
10. Wang, W., Jiang, J., Ballard, C. E., and Wang, B. (1999) Prodrug approaches to the improved delivery of peptide drugs. Curr. Pharm. Des. 5, 265-287.
11. Denny, W. A. (2001) Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36, 577-595.
12. Denny, W. A. (2003) Prodrugs for gene-directed enzyme-prodrug therapy (suicide gene therapy). J. Biomed. Biotechnol. 2003, 48-70.
13. Yatvin, M. B., Li, W., Meredith, M. J., and Shenoy, M. A. (1999) Improved uptake and retention of lipophilic prodrug to improve treatment of HIV. Adv. Drug Deliv. Rev. 39, 165-182.
14. Niculescu-Duvaz, I., Friedlos, F., Niculescu-Duvaz, D., Davies, L., and Springer, C. J. (1999) Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anticancer Drug Des. 14, 517-538.
15. Tan, X., Chu, C. K., and Boudinot, F. D. (1999) Development and optimization of anti-HIV nucleoside analogs and prodrugs: A review of their cellular pharmacology, structure-activity relationships and pharmacokinetics. Adv. Drug Deliv. Rev. 39, 117-151.
16. Wiebe, L. I., and Knaus, E. E. (1999) Concepts for the design of anti-HIV nucleoside prodrugs for treating cephalic HIV infection. Adv. Drug Deliv. Rev. 39, 63-80.
17. Gunaseelan, S., Debrah, O., Wan, L., Leibowitz, M. J., Rabson, A. B., Stein, S., and Sinko, P. J. (2004) Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay. Bioconjugate Chem. 15, 1322-1333.
18. Jain, R., Agarwal, S., Majumdar, S., Zhu, X., Pal, D., and Mitra, A. K. (2005) Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification. Int. J. Pharm. 303, 8-19.
19. Luo, S., Kansara, V. S., Zhu, X., Mandava, N. K., Pal, D., and Mitra, A. K. (2006) Functional characterization of sodium-dependent multivitamin transporter in MDCK-MDR1 cells and its utilization as a target for drug delivery. Mol. Pharm. 3, 329-339.
20. Gatell, J. M. (2001) From amprenavir to GW433908. J. HIV Ther. 6, 95-99.
21. Sorbera, L. A., Martin, L., Castaner, J., and Castaner, R. M. (2001) Fosamprenavir. Anti-HIV HIV protease inhibitor. Drugs Future 26, 224-231.
22. Chapman, T. M., Plosker, G. L., and Perry, C. M. (2004) Fosamprenavir: a review of its use in the management of antiretroviral therapy-naive patients with HIV infection. Drugs 64, 2101-2124.
23. Becker, S., and Thornton, L. (2004) Fosamprenavir: advancing HIV protease inhibitor treatment options. Exp. Opin. Pharmacother. 5, 1995-2005.
24. Furfine, E. S., Baker, C. T., Hale, M. R., Reynolds, D. J., Salisbury, J. A., Searle, A. D., Studenberg, S. D., Todd, D., Tung, R. D., and Spaltenstein, A. (2004) Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob. Agents Chemother. 48, 791-798.
25. Flexner, C. W. (2002) Pharmacology and drug interactions of HIV protease inhibitors. Infect. Dis. Ther. 25, 139-159.
26. Fromm, M. F. (2000) P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38, 69-74.
27. Farese-Di Giorgio, A., Rouquayrol, M., Greiner, J., Aubertin, A.-M., Vierling, P., and Guedj, R. (2000) Synthesis and anti-HIV activity of prodrugs derived from saquinavir and indinavir. Antivir. Chem. Chemother. II, 97-110.
28. Gaucher, B., Rouquayrol, M., Roche, D., Greiner, J., Aubertin, A.-M., and Vierling, P. (2004) Prodrugs of HIV protease inhibitors-saquinavir, indinavir and nelfinavir-derived from diglycerides or amino acids: synthesis, stability and anti-HIV activity. Org. Biomol. Chem. 2, 345-357.
29. Rouquayrol, M., Gaucher, B., Greiner, J., Aubertin, A.-M., Vierling, P., and Guedj, R. (2001) Synthesis and anti-HIV activity of glucose-containing prodrugs derived from saquinavir, indinavir and nelfinavir. Carbohydr. Res. 336, 161-180.
30. Rouquayrol, M., Gaucher, B., Roche, D., Greiner, J., and Vierling, P. (2002) Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir Across Caco-2 Cell Monolayers. Pharm. Res. 19, 1704-1712.
31. Barratt, G., and Schuber, F. (1993) Targeting of liposomes with mannose-terminated ligands, in Liposome Technology, 2nd Ed. (Gregoriadis, G. Ed.) Vol. 3, pp 199-218, CRC, Boca Raton, U.S.A.
32. Molema, G., Jansen, R. W., Pauwels, R., de Clercq, E., and Meijer, D. K. (1990) Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. Biochem. Pharmacol. 40, 2603-2610.
33. Bolmstedt, A. J., O'Keefe, B. R., Shenoy, S. R., McMahon, J. B., and Boyd, M. R. (2001) Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol. Pharmacol. 59, 949-954.
34. Ferkol, T., Perales, J. C., Mularo, F., and Hanson, R. W. (1996) Receptor-mediated gene transfer into macrophages. Proc. Natl. Acad. Sci. U.S.A. 93, 101-105.
35. Linehan, S. A., Martinez-Pomares, L., and Gordon, S. (2000) Macrophage lectins in host defence. Microb. Infect. 2, 279-288.
36. Martinez-Pomares, L., Linehan, S. A., Taylor, P. R., and Gordon, S. (2001) Binding properties of the mannose receptor. Immunobiology 204, 527-535.
37. Diebold, S. S., Plank, C., Cotten, M., Wagner, E., and Zenke, M. (2002) Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat. Cell Mol. Genet. 27, 65-74.
38. Grandjean, C., Angyalosi, G., Loing, E., Adriaenssens, E., Melnyk, O., Pancre, V., Auriault, C., and Gras-Masse, H. (2001) Novel hyperbranched glycomimetics recognized by the human mannose receptor: quinic or shikimic acid derivatives as mannose bioisosteres. ChemBioChem 2, 747-757.
39. Lee, R. T., Ichikawa, Y., Fay, M., Drickamer, K., Shao, M., and Lee, Y. C. (1991) Ligand-binding characteristics of rat serum-type mannose-binding protein (MBP-A). Homology of binding site architecture with mammalian and chicken hepatic lectins. J. Biol. Chem. 266, 4810-4815.
40. Gouyette, C., Neumann, J. M., Fauve, R., and Huynh-Dinh, T. (1989) 6- and 1- Substituted mannosyl phosphotriesters as lipophilic macrophage-targeted carriers of antiviral nucleosides. Tetrahedron Lett. 30, 6019-6022.
41. Muller, C. D., and Schuber, F. (1989) Neo-mannosylated liposomes: synthesis and interaction with mouse Kupffer cells and resident peritoneal macrophages. Biochim. Biophys. Acta 986, 97-105.
42. Park, K.-H., Sung, W. J., Kim, S., Kim, D. H., Akaike, T., and Chung, H.-M. (2005) Specific interaction of mannosylated glycopolymers with macrophage cells mediated by mannose receptor. J. Biosci. Bioeng. 99, 285-289.
43. Frappier, F., Audinot, M., Beaucourt, J. P., Sergent, L., and Lukacs, G. (1982) Mechanism of the backbone rearrangement of amino steroids. A carbon-13 and tritium nuclear magnetic resonance spectroscopic study of isoconessine, neoconessine and the corresponding polydeuterated and polytritiated species. J. Org. Chem. 47, 3783-3785.
44. Huckstep, M., Taylor, R. J. K., and Caton, M. P. L. (1982) A convenient method of preparing the leukotriene precursor methyl 5-oxopentanoate. Synthesis 881-882.
45. Bashyal, B. P., Fleet, G. W. J., Gough, M. J., and Smith, P. W. (1987) Synthesis of the α-mannosidase inhibitors swainsonine [(1S,2R,8R,8aR)-1,2, 8-trihydroxyoctahydroindolizine] and 1,4-dideoxy-1,4-imino-D-mannitol from mannose. Tetrahedron 43, 3083-3093.
46. Winnik, F. M., Carver, J. P., and Krepinsky, J. J. (1982) Syntheses of model oligosaccharides of biological significance. 2. Synthesis of a tetramannoside and of two lyxose-containing trisaccharides. J. Org. Chem. 47, 2701-2707.
47. Chung, S.-K., and Moon, S.-H. (1994) Synthesis and biological activities of (4,6-di-O-phosphonato-β-D-mannopyranosyl)- methylphosphonate as an analog of 1L-myo-inositol 1,4,5-trisphosphate. Carbohydr. Res. 260, 39-50.
48. Bodanszky, M., and Bodanszky, A. (1984) The Practice of Peptide Synthesis, Springer-Verlag, Berlin.
49. Dasser, M., Chretien, F., and Chapleur, Y. (1990) A facile and stereospecific synthesis of L-glycero-D-manno-heptose and some derivatives. J. Chem. Soc., Perkin Trans. 1, 3091-3094.
50. Maeda, H., Matsumoto, S., Koide, T., and Ohmori, H. (1998) Dehydroxy substitution reactions of the anomeric hydroxy groups in some protected sugars initiated by anodic oxidation of triphenylphosphine. Chem. Pharm. Bull. 46, 939-943.
51. Marra, A., Scherrmann, M.-C., Dondoni, A., Casnati, A., Minari, P., and Ungaro, R. (1994) Sugar calixarenes: synthesis of calix[4]-arenes with O-glycosyl substituents at upper and lower edges. Angew. Chem., Int. Ed. Engl. 33, 2479-2481.
52. McAdam, D. P., and Stick, R. V. (1988) The treatment of some carbohydrate alcohols and diols with N-dibromomethylene-N,N-dialkylammonium bromides: a synthesis of glycosyl bromides. Aust. J. Chem. 41, 563-573.
53. Nguyen, H. M., Poole, J. L., and Gin, D. Y. (2001 ) Chemoselective iterative dehydrative glycosylation. Angew. Chem., Int. Ed. 40, 414-417.
54. Stepowska, H., and Zamojski, A. (1994) A convenient preparation of 5-benzyl ethers of D-gluco- and D-manno-furanose derivatives. Carbohydr. Res. 265, 133-137.
55. Ferrieres, V., Roussel, M., Gelin, M., and Plusquellec, D. (2001) A new approach to a disaccharidic hapten containing a galactofuranosyl entity. J. Carbohydr. Chem. 20, 855-865.
56. Nguyen, H. M., Chen, Y., Duron, S. G., and Gin, D. Y. (2001) Sulfide-mediated dehydrative glycosylation. J. Am. Chem. Soc. 123, 8766-8772.
57. Chretien, F., Chapleur, Y., Castro, B., and Gross, B. (1980) Alkyloxytris(dimethylamino)phosphonium salts. Part 21. Anomeric hydroxy-group activation of 2,3:4,6-di-O-isopropylidene-α-D-mannopyranose, thioglycosylation, and glycosylation. J. Chem. Soc., Perkin Trans. 1, 381-384.
58. Bock, K., and Pedersen, C. (1983) Carbon-13 nuclear magnetic resonance spectroscopy of monosaccharides. Adv. Carbohydr. Chem. Biochem. 41, 27-66.
59. Sugawara, T., Irie, K., Iwasawa, H., Yoshikawa, T., Okuno, S., Watanabe, H. K., KaCo, T., Shibukawa, M., and Ito, Y. (1992) Synthesis of omega-(methoxycarbon)alkyl and 9-(methoxycarbonyl)-3,6-dioxanonyl glycopyranosides for the preparation of carbohydrate-protein conjugates. Carbohydr. Res. 230, 117-149.
60. Sequin, U. (1981) Carbon-13 NMR spectral differences between corresponding methyl esters, phenyl esters and 2-substituted chromones. Helv. Chim. Acta 64, 2654-2664.
61. Schuster, I. I. (1985) A carbon-13 NMR study of electronic effects in the hydrogen bonding of trifluoroacetic acid with substituted benzenes, 1- and 2-substituted naphthalenes, and 9-substituted anthracenes in chloroform. J. Org. Chem. 50, 1656-1662.
62. Lebon, F., and Ledecq, M. (2000) Approaches to the design of effective HIV-1 protease inhibitors. Curr. Med. Chem. 7, 455-477.
63. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J., and De Clercq, E. (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309-321.
64. Genu-Dellac, C., Gosselin, G., Puech, F., Henry, J. C., Aubertin, A. M., Obert, G., Kirn, A., and Imbach, J. L. (1991) Systematic synthesis and antiviral evaluation of α-L-arabinofuranosyl and 2′-deoxy-α-L-erythro- pentofuranosyl nucleosides of the five naturally occurring nucleic acid bases. Nucleosides Nucleotides 10, 1345-1376.
65. Moog, C., Wick, A., Le Ber, P., Kirn, A., and Aubertin, A.-M. (1994) Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res. 24, 275-288.
66. West, M. L., and Fairlie, D. P. (1995) Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 16, 67-74.
67. Kim, R. B., Fromm, M. F., Wandel, C., Leake, B., Wood, A. J. J., Roden, D. M., and Wilkinson, G. R. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101, 289-294.
68. Aungst, B. J., Nguyen, N. H., Bulgarelli, J. P., and Oates-Lenz, K. (2000) The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds. Pharm. Res. 17, 1175-1180.
69. Artursson, P. (1991) Cell cultures as models for drug absorption across the intestinal mucosa. Crit. Rev. Ther. Drug Carrier Syst. 8, 305-330.
70. Augustijns, P., Annaert, P., Heylen, P., Van den Mooter, G., and Kinget, R. (1998) Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166, 45-53.
71. Annaert, P., Gosselin, G., Pompon, A., Benzaria, S., Valette, G., Imbach, J. L., Naesens, L., Hatse, S., De Clercq, E., Van Den Mooter, G., Kinget, R., and Augustijns, P. (1998) Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 monolayers. Pharm. Res. 15, 239-245.
72. Artursson, P., Palm, K., and Luthman, K. (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46, 27-43.
73. Gres, M.-C., Julian, B., Bourrie, M., Meunier, V., Roques, C., Berger, M., Boulenc, X., Berger, Y., and Fabre, G. (1998) Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm. Res. 15, 726-733.
74. Gan, L. S., Eads, C., Niederer, T., Bridgers, A., Yanni, S., Hsyu, P. H., Pritchard, F. J., and Thakker, D. (1994) Use of Caco-2 cells as an in vitro intestinal absorption and metabolism model. Drug Dev. Ind. Pharm. 20, 615-631.
75. Lu, S., Gough, A. W., Bobrowski, W. F., and Stewart, B. H. (1996) Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes. J. Pharm. Sci. 85, 270-273.
76. Bhhatarai, B., and Garg, R. (2005) From SAR to comparative QSAR: role of hydrophobicity in the design of 4-hydroxy-5,6-dihydropyran-2-ones HIV-1 protease inhibitors. Bioorg. Med. Chem. 13, 4078-4084.